Definium Therapeutics (NASDAQ:DFTX) Shares Up 8.3% – Still a Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX)’s share price rose 8.3% during trading on Tuesday . The stock traded as high as $17.22 and last traded at $17.06. Approximately 1,438,534 shares changed hands during trading, a decline of 27% from the average daily volume of 1,983,315 shares. The stock had previously closed at $15.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on DFTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, January 22nd. Robert W. Baird set a $37.00 price target on shares of Definium Therapeutics in a research report on Thursday, January 29th. Canaccord Genuity Group lifted their price objective on shares of Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Chardan Capital raised shares of Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Royal Bank Of Canada lifted their price target on Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Definium Therapeutics presently has an average rating of “Buy” and a consensus target price of $35.22.

Definium Therapeutics Stock Up 7.3%

The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30. The business’s 50 day moving average price is $14.79 and its 200 day moving average price is $12.36. The firm has a market cap of $1.66 billion, a PE ratio of -8.28 and a beta of 2.57.

Insiders Place Their Bets

In other news, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $148,279.40. Following the sale, the insider directly owned 282,576 shares of the company’s stock, valued at $3,715,874.40. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the sale, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. The trade was a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 42,667 shares of company stock worth $561,071. Corporate insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Institutional investors have recently modified their holdings of the company. Marshall Wace LLP increased its position in Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after purchasing an additional 828,067 shares during the period. Commodore Capital LP lifted its holdings in shares of Definium Therapeutics by 10.5% in the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after buying an additional 475,000 shares during the period. Orbimed Advisors LLC purchased a new stake in shares of Definium Therapeutics in the third quarter valued at approximately $4,337,000. Rosalind Advisors Inc. grew its holdings in Definium Therapeutics by 78.6% during the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock worth $8,842,000 after acquiring an additional 330,000 shares during the period. Finally, Two Sigma Investments LP grew its holdings in Definium Therapeutics by 424.9% during the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after acquiring an additional 239,965 shares during the period. 27.91% of the stock is owned by institutional investors and hedge funds.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.